Source: Eur Respir J 2015; 46: 1843-1844
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Bhuniya Sourin, Mohapatra Prasanta Raghab, Panigrahi Manoj Kumar, Behera Priyadarshini, Pradhan Gourhari. Linezolid in drug-resistant tuberculosis: haste makes waste. Eur Respir J 2015; 46: 1843-1844

Member's Comments

No comment yet.

Related content which might interest you: Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004 Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient Source: Eur Respir J 2014; 43: 292-294 Year: 2004 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019 Year: 2020 Mefloquine as a potential drug against multidrug-resistant tuberculosis Source: Eur Respir J 2015; 46: 1503-1505 Year: 2015 Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary? Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019 Year: 2019 Multidrug- and extensively drug-resistant tuberculosis: an emerging threat Source: Eur Respir Rev 2009; 18: 195-197 Year: 2009 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017 Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Extensively drug-resistant tuberculosis: back to the future Source: Eur Respir J 2010; 36: 475-477 Year: 2010